These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

871 related articles for article (PubMed ID: 29356032)

  • 41. Week 4 Liver Fat Reduction on MRI as an Early Predictor of Treatment Response in Participants with Nonalcoholic Steatohepatitis.
    Jiang H; Chen HC; Lafata KJ; Bashir MR
    Radiology; 2021 Aug; 300(2):361-368. PubMed ID: 34060937
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnosis and Monitoring of Nonalcoholic Steatohepatitis: Current State and Future Directions.
    Kadi D; Loomba R; Bashir MR
    Radiology; 2024 Jan; 310(1):e222695. PubMed ID: 38226882
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacologic Treatment Strategies for Nonalcoholic Steatohepatitis.
    Esteban JPG; Asgharpour A
    Gastroenterol Clin North Am; 2020 Mar; 49(1):105-121. PubMed ID: 32033758
    [TBL] [Abstract][Full Text] [Related]  

  • 44. MRI Quantification of Placebo Effect in Nonalcoholic Steatohepatitis Clinical Trials.
    Nedrud MA; Chaudhry M; Middleton MS; Moylan CA; Lerebours R; Luo S; Farjat A; Guy C; Loomba R; Abdelmalek MF; Sirlin CB; Bashir MR
    Radiology; 2023 Mar; 306(3):e220743. PubMed ID: 36318027
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The metabolic influence of duodenal mucosal resurfacing for nonalcoholic fatty liver disease.
    Chuang TJ; Ko CW; Shiu SI
    Medicine (Baltimore); 2023 Oct; 102(40):e35147. PubMed ID: 37800801
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
    Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
    Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gd-EOB-DTPA-enhanced T1ρ imaging vs diffusion metrics for assessment liver inflammation and early stage fibrosis of nonalcoholic steatohepatitis in rabbits.
    Xie Y; Zhang H; Jin C; Wang X; Wang X; Chen J; Xu Y
    Magn Reson Imaging; 2018 May; 48():34-41. PubMed ID: 29278765
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of Nonalcoholic Fatty Liver Disease in Rats Using Quantitative Dynamic Contrast-Enhanced MRI.
    Wu Z; Cheng ZL; Yi ZL; Xie MW; Zeng H; Lu LJ; Xu X; Shen J
    J Magn Reson Imaging; 2017 May; 45(5):1485-1493. PubMed ID: 27606822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
    Papatheodoridi M; Cholongitas E
    Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
    Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial).
    Loomba R; Sirlin CB; Ang B; Bettencourt R; Jain R; Salotti J; Soaft L; Hooker J; Kono Y; Bhatt A; Hernandez L; Nguyen P; Noureddin M; Haufe W; Hooker C; Yin M; Ehman R; Lin GY; Valasek MA; Brenner DA; Richards L;
    Hepatology; 2015 Apr; 61(4):1239-50. PubMed ID: 25482832
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prediction of nonalcoholic fatty liver disease (NAFLD) activity score (NAS) with multiparametric hepatic magnetic resonance imaging and elastography.
    Yin Z; Murphy MC; Li J; Glaser KJ; Mauer AS; Mounajjed T; Therneau TM; Liu H; Malhi H; Manduca A; Ehman RL; Yin M
    Eur Radiol; 2019 Nov; 29(11):5823-5831. PubMed ID: 30887196
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Application of Ultrasound and Shear Wave Elastography Imaging in a Rat Model of NAFLD/NASH.
    Morin J; Swanson TA; Rinaldi A; Boucher M; Ross T; Hirenallur-Shanthappa D
    J Vis Exp; 2021 Apr; (170):. PubMed ID: 33970131
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Pilot Comparative Study of Quantitative Ultrasound, Conventional Ultrasound, and MRI for Predicting Histology-Determined Steatosis Grade in Adult Nonalcoholic Fatty Liver Disease.
    Paige JS; Bernstein GS; Heba E; Costa EAC; Fereirra M; Wolfson T; Gamst AC; Valasek MA; Lin GY; Han A; Erdman JW; O'Brien WD; Andre MP; Loomba R; Sirlin CB
    AJR Am J Roentgenol; 2017 May; 208(5):W168-W177. PubMed ID: 28267360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative Liver MRI-Biopsy Correlation in Pediatric and Young Adult Patients With Nonalcoholic Fatty Liver Disease: Can One Be Used to Predict the Other?
    Dillman JR; Trout AT; Costello EN; Serai SD; Bramlage KS; Kohli R; Xanthakos SA
    AJR Am J Roentgenol; 2018 Jan; 210(1):166-174. PubMed ID: 29045180
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-invasive evaluation of NAFLD and the contribution of genes: an MRI-PDFF-based cross-sectional study.
    Yang A; Zhu X; Zhang L; Zhang Y; Zhang D; Jin M; Niu J; Zhang H; Ding Y; Lv G
    Hepatol Int; 2022 Oct; 16(5):1035-1051. PubMed ID: 35829866
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).
    Drescher HK; Weiskirchen S; Weiskirchen R
    Cells; 2019 Aug; 8(8):. PubMed ID: 31394730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease.
    Schwimmer JB; Middleton MS; Behling C; Newton KP; Awai HI; Paiz MN; Lam J; Hooker JC; Hamilton G; Fontanesi J; Sirlin CB
    Hepatology; 2015 Jun; 61(6):1887-95. PubMed ID: 25529941
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MRI-determined liver fat correlates with risk of metabolic syndrome in patients with nonalcoholic fatty liver disease.
    Chen J; Duan S; Ma J; Wang R; Chen J; Liu X; Xue L; Xie S; Yao S
    Eur J Gastroenterol Hepatol; 2020 Jun; 32(6):754-761. PubMed ID: 32091437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.